Conferences & Events
Filter News
Found 120,737 articles
-
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
3/18/2024
First Wave BioPharma, Inc., announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference taking place May 18-21, 2024, in Washington, D.C.
-
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
3/18/2024
Aptevo Therapeutics Inc. announced that the Company is participating in The Springtime Event, a Bio-Europe conference occurring March 18-20, 2024 in Barcelona, Spain.
-
Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
3/18/2024
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions Cevira®.
-
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platformPoster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform
3/18/2024
OBI Pharma, Inc. announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate.
-
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
3/18/2024
KalVista Pharmaceuticals, Inc. announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.
-
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
3/18/2024
Mainz Biomed N.V. will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
-
SHINE Technologies to Exhibit at 7th Annual Theranostics World Congress
3/18/2024
SHINE Technologies will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments, at the 7th Theranostic World Congress (TWC), March 22-24 in Santiago, Chile.
-
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
3/18/2024
Zevra Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Thursday, March 28, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the fourth quarter and full year 2023.
-
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
3/18/2024
Cybin Inc today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX.
-
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
3/18/2024
Humacyte, Inc. will release its financial results for the fourth quarter and year ended December 31, 2023, on Friday, March 22, 2024.
-
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
3/18/2024
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS).
-
Aruna Bio to Participate in Upcoming Investor Conferences
3/18/2024
Aruna Bio, Inc. today announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at upcoming investor conferences.
-
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
3/18/2024
Indaptus Therapeutics, Inc. announces that its CEO, Jeffrey Meckler, will present and participate in an open Q&A on Tribe Public’s Webinar titled, “Fully Engaging The Human Immune System To Cure Disease.”
-
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
3/18/2024
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium.
-
Medigene AG to report full year 2023 financial results on March 28, 2024
3/18/2024
Medigene AG will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024.
-
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson's ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
3/18/2024
Johnson & Johnson announced today that new data will be featured at this year's European Lung Cancer Congress (ELCC) taking place from March 20 to 23 in Prague, Czech Republic, highlighting the Company's commitment to transform the treatment of lung cancer through the ongoing study of RYBREVANT® (amivantamab)-based regimens in the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
-
Pattern to Present at 23rd Annual Needham Virtual Healthcare Conference
3/18/2024
Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8 – 11, 2024.
-
Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024
3/18/2024
Carina Biotech Limited (Carina) today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
-
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
3/18/2024
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Association (NHIA) 2024 Conference.
-
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024
3/18/2024
Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV) today announced that revenues for the quarter ended January 31, 2024 were approximately $2.4 million, a decrease of approximately $1.9 million when compared to the same period last year.